Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) – study protocol paper for a phase III multicentre, open-label randomised controlled trial
Finbar Slevin(University of Leeds), Ann Henry(University of Leeds), Samantha Noutch(University of Leeds), Mohan Hingorani(Hull and East Yorkshire Hospitals NHS Trust), Caroline Dive(University of Manchester), James Talbot(Royal Marsden NHS Foundation Trust), Matthew Carter(University of Southampton), Ananya Choudhury(University of Manchester), Alexandra Gilbert(St James's University Hospital), Omar Din(Sheffield Teaching Hospitals NHS Foundation Trust), Olivia Naismith(Royal Marsden NHS Foundation Trust), S. Alexander(Royal Marsden NHS Foundation Trust), Sarah Brown(University of Leeds), Pedro F. Oliveira(Rede de Química e Tecnologia), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Christopher Pagett(Leeds Teaching Hospitals NHS Trust), Louise Murray(Leeds Teaching Hospitals NHS Trust), Sean Girvan(University of Leeds), Joanne Webster(University of Leeds), Alexandra Smith(University of Leeds), Alexandra Clipson(Cancer Research UK), Suneil Jain(Queen's University Belfast), J. Lilley(Leeds Teaching Hospitals NHS Trust)
Cited by 12
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Multiple newly identified loci associated with prostate cancer susceptibility
|Nature Genetics|2008|850
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767